Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months

  • Park, So Yun (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Sung Hoon (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Chae, Hee Dong (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Chung-Hoon (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kang, Byung Moon (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2016.08.24
  • Accepted : 2016.10.25
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To evaluate the efficacy and safety of dienogest treatment in patients who had received dienogest for 12 months or more to treat endometriosis. Methods: We analyzed the clinical data of 188 women with endometriosis who had been treated with 2 mg of dienogest once a day for 12 months or more at a single institute. We evaluated changes in endometriosis-associated pain and endometrioma size, recurrence rate, and adverse events following dienogest administration. Bone mineral density (BMD) was measured in patients who were prescribed dienogest for more than 18 months. Results: Pain was significantly reduced at 12 months after dienogest medication. In those treated with dienogest due to recurrent endometrioma, the size of the endometrioma was significantly decreased at the 12-month and 18-month follow-ups. We found only one case of sonographic recurrence during dienogest administration among those who were treated postoperatively to prevent recurrence (1 of 114, 0.9%). The most common adverse drug reaction was uterine bleeding (3.2%), and other adverse events were generally tolerable and associated with low discontinuation rates (5.2%). Among the 50 patients in whom BMD was measured, 10 patients (20%) had a Z-score below the expected range for age. Conclusion: The administration of dienogest for a year or more seems to be highly effective in preventing recurrence after surgery, reducing endometriosis-associated pain, and decreasing the size of recurrent endometrioma, with a favorable safety and tolerability profile. However, BMD should be checked in patients on long-term medication due to possible bone loss in some women.

Keywords

References

  1. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24:235-58. https://doi.org/10.1016/S0889-8545(05)70302-8
  2. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-99. https://doi.org/10.1016/S0140-6736(04)17403-5
  3. Kim SH, Chae HD, Kim CH, Kang BM. Update on the treatment of endometriosis. Clin Exp Reprod Med 2013;40:55-9. https://doi.org/10.5653/cerm.2013.40.2.55
  4. Vercellini P, Crosignani P, Somigliana E, Vigano P, Frattaruolo MP, Fedele L. ‘Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis. Hum Reprod 2011;26:3-13. https://doi.org/10.1093/humrep/deq302
  5. Foster RH, Wilde MI. Dienogest. Drugs 1998;56:825-33. https://doi.org/10.2165/00003495-199856050-00007
  6. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010;151:193-8. https://doi.org/10.1016/j.ejogrb.2010.04.002
  7. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010;25:633-41. https://doi.org/10.1093/humrep/dep469
  8. Petraglia F, Hornung D, Seitz C, Faustmann T, Gerlinger C, Luisi S, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2012;285:167-73. https://doi.org/10.1007/s00404-011-1941-7
  9. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997;67:817-21. https://doi.org/10.1016/S0015-0282(97)81391-X
  10. Exacoustos C, Zupi E, Carusotti C, Rinaldo D, Marconi D, Lanzi G, et al. Staging of pelvic endometriosis: role of sonographic appearance in determining extension of disease and modulating surgical approach. J Am Assoc Gynecol Laparosc 2003;10:378-82. https://doi.org/10.1016/S1074-3804(05)60266-6
  11. Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis: a randomized, double-blind, multicenter, controlled trial. Fertil Steril 2009;91:675-81. https://doi.org/10.1016/j.fertnstert.2007.12.080
  12. Sugimoto K, Nagata C, Hayashi H, Yanagida S, Okamoto A. Use of dienogest over 53 weeks for the treatment of endometriosis. J Obstet Gynaecol Res 2015;41:1921-6. https://doi.org/10.1111/jog.12811
  13. Choi J, Jo M, Lee E, Lee DY, Choi D. Dienogest enhances autophagy induction in endometriotic cells by impairing activation of AKT, ERK1/2, and mTOR. Fertil Steril 2015;104:655-64.e1. https://doi.org/10.1016/j.fertnstert.2015.05.020
  14. Hayashi A, Tanabe A, Kawabe S, Hayashi M, Yuguchi H, Yamashita Y, et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovarian Res 2012;5:31. https://doi.org/10.1186/1757-2215-5-31

Cited by

  1. Meta-Analysis of Chinese Traditional Medicine Bushen Huoxue Prescription for Endometriosis Treatment vol.2017, pp.None, 2017, https://doi.org/10.1155/2017/5416423
  2. Clinical dynamics of Dienogest for the treatment of endometriosis: from bench to bedside vol.13, pp.6, 2016, https://doi.org/10.1080/17425255.2017.1297421
  3. Efficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma vol.25, pp.3, 2016, https://doi.org/10.1177/1933719117725820
  4. Gastrointestinal and Urinary Tract Endometriosis: A Review on the Commonest Locations of Extrapelvic Endometriosis vol.2018, pp.None, 2016, https://doi.org/10.1155/2018/3461209
  5. Clinical experience of long-term use of dienogest after surgery for ovarian endometrioma vol.61, pp.1, 2016, https://doi.org/10.5468/ogs.2018.61.1.111
  6. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice vol.298, pp.4, 2016, https://doi.org/10.1007/s00404-018-4864-8
  7. Symptom-alleviating effect and adverse effect of dienogest in Korean women with endometriosis vol.34, pp.11, 2016, https://doi.org/10.1080/09513590.2018.1469610
  8. The clinical outcome of Dienogest treatment followed by in vitro fertilization and embryo transfer in infertile women with endometriosis vol.12, pp.None, 2016, https://doi.org/10.1186/s13048-019-0597-y
  9. Significant risk factors for malignant transformation of ovarian endometrioma during dienogest treatment: a case report and retrospective study vol.13, pp.1, 2016, https://doi.org/10.1186/s13256-019-2236-z
  10. Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study vol.27, pp.3, 2016, https://doi.org/10.1007/s43032-019-00094-5
  11. Safety of Dienogest and Other Hormonal Treatments for Endometriosis in Real-World Clinical Practice (VIPOS): A Large Noninterventional Study vol.37, pp.5, 2016, https://doi.org/10.1007/s12325-020-01331-z
  12. Use of dienogest in endometriosis: a narrative literature review and expert commentary vol.36, pp.5, 2020, https://doi.org/10.1080/03007995.2020.1744120
  13. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure vol.26, pp.4, 2016, https://doi.org/10.1093/humupd/dmaa009
  14. Effect of Dienogest therapy on the size of the endometrioma vol.36, pp.8, 2016, https://doi.org/10.1080/09513590.2020.1725965
  15. Long-Term Medical Therapy after Laparoscopic Excision of Ovarian Endometriomas: Can We Reduce and Predict the Risk of Recurrence? vol.86, pp.1, 2016, https://doi.org/10.1159/000514310
  16. Ovarian endometriosis and fertility preservation problem vol.23, pp.2, 2021, https://doi.org/10.26442/20795696.2021.2.200822
  17. Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what’s the best choice? vol.37, pp.5, 2016, https://doi.org/10.1080/09513590.2021.1892632
  18. The Effects of Cabergoline Compared to Dienogest in Women with Symptomatic Endometrioma vol.3, pp.2, 2016, https://doi.org/10.1142/s2661318221500067
  19. Dienogest reduces endometrioma volume and endometriosis-related pain symptoms vol.41, pp.8, 2016, https://doi.org/10.1080/01443615.2020.1867962
  20. A randomized, double‐blind, placebo‐controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis vol.156, pp.1, 2016, https://doi.org/10.1002/ijgo.13677